Dr Hafron on the FDA Approval of Adjuvant Atezolizumab in MRD+ MIBC

Jason Hafron, MD, chief medical officer and medical director of clinical research at the Michigan Institute, as well as a professor of urology at the William Beaumont School of Medicine, Oakland University, discussed the significance of the FDA approval of adjuvant atezolizumab (Tecentriq) for muscle-invasive bladder cancer (MIBC) with circulating tumor DNA (ctDNA) molecular residual disease (MRD).

On May 15, 2026, the FDA approved both atezolizumab and atezolizumab plus hyaluronidase-tqjs (Tecentriq Hybreza; subcutaneous atezolizumab) as adjuvant treatments for adult patients with MIBC after cystectomy who have ctDNA MRD, as determined by an FDA-authorized test.

The regulatory decision was supported by robust data from the phase 3 IMvigor011 trial (NCT04660344), in which patients treated with adjuvant atezolizumab achieved a median disease-free survival (DFS) of 9.9 months (95% CI, 7.2-12.7) vs 4.8 months (95% CI, 4.1-8.3) in the placebo arm (HR, 0.64; 95% CI, 0.47-0.87; P = .0047). Furthermore, the agent demonstrated a meaningful overall survival (OS) benefit, with a median OS of 32.8 months (95% CI, 27.7-not estimable [NE]) vs 21.1 months (95% CI, 14.7-NE) for placebo (HR, 0.59; 95% CI, 0.39-0.90; P = .0131).

In tandem with the therapeutic approval, the FDA also approved Signatera CDx as a companion diagnostic to identify patients with ctDNA MRD eligible for treatment.

Hafron emphasized that IMvigor011 is the first trial to prospectively utilize a biomarker in this setting, providing level one evidence that ctDNA-informed treatment can substantially improve outcomes. He characterized ctDNA as a "disruptive technology" that allows the field to precisely target therapies toward the patients most likely to derive benefit. These strong results represent just the beginning of a broader transition toward biomarker-driven strategies in the management of bladder cancer, he concluded.